← All trials
NCT07121946
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2025
- Primary completion
- Feb 29, 2028
- Completion date
- Feb 29, 2028
- First posted
- Aug 14, 2025
- Last posted
- Nov 25, 2025
- Enrollment
- 42
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- LTZ Therapeutics, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.